Hakan Kardes Sells 20,500 Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Hakan Kardes sold 20,500 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $13.06, for a total transaction of $267,730.00. Following the completion of the sale, the insider now owns 355,444 shares of the company’s stock, valued at approximately $4,642,098.64. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Hakan Kardes also recently made the following trade(s):

• On Friday, November 1st, Hakan Kardes sold 4,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.98, for a total value of $58,410.00.
• On Thursday, September 12th, Hakan Kardes sold 25,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $11.48, for a total value of $287,000.00.

Alignment Healthcare Price Performance

Shares of NASDAQ:ALHC opened at $14.15 on Thursday. The stock has a market capitalization of $2.71 billion, a P/E ratio of -18.38 and a beta of 1.45. The business has a 50-day moving average of $10.98 and a two-hundred day moving average of $8.96. Alignment Healthcare, Inc. has a fifty-two week low of $4.46 and a fifty-two week high of $14.25. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Tuesday, October 29th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). Alignment Healthcare had a negative return on equity of 108.69% and a negative net margin of 5.84%. The firm had revenue of $692.43 million during the quarter, compared to analyst estimates of $662.11 million. During the same period in the previous year, the company earned ($0.19) EPS. The company’s revenue for the quarter was up 51.6% on a year-over-year basis. On average, equities research analysts predict that Alignment Healthcare, Inc. will post -0.68 EPS for the current fiscal year.

Institutional Trading of Alignment Healthcare

Large investors have recently modified their holdings of the company. Virtu Financial LLC bought a new position in Alignment Healthcare in the 1st quarter worth $57,000. Principal Financial Group Inc. bought a new stake in Alignment Healthcare during the first quarter valued at about $57,000. nVerses Capital LLC acquired a new stake in shares of Alignment Healthcare in the third quarter valued at about $95,000. Creative Planning increased its stake in shares of Alignment Healthcare by 20.0% in the third quarter. Creative Planning now owns 12,442 shares of the company’s stock worth $147,000 after purchasing an additional 2,072 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Alignment Healthcare by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 39,570 shares of the company’s stock worth $196,000 after purchasing an additional 3,334 shares during the last quarter. 86.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ALHC. Robert W. Baird increased their price target on shares of Alignment Healthcare from $10.00 to $11.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 14th. Piper Sandler reissued an “overweight” rating and set a $10.00 target price (up previously from $8.00) on shares of Alignment Healthcare in a research note on Tuesday, August 6th. KeyCorp began coverage on shares of Alignment Healthcare in a report on Friday, October 11th. They set a “sector weight” rating on the stock. UBS Group increased their price objective on Alignment Healthcare from $9.00 to $12.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, Stifel Nicolaus boosted their target price on Alignment Healthcare from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, July 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.33.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.